Pfizer bails out on collaboration with Organon

Pfizer has decided to drop out of its collaboration with Organon to develop asenapine for schizophrenia and bipolar disease after completing a review of the compound and its place in the pharma giant's "overall portfolio." Last October researchers issued interim Phase III data that suggested they may not have enough evidence to back an NDA. Organon says it will push ahead on its own for now, and may look for another partner to complete work on the drug. In the meantime, Organon parent company Akzo Nobel says the move by Pfizer to drop out of the program will not alter a planned stock flotation for Organon. Pfizer is returning all intellectual property rights and data to Organon as part of an "orderly" transfer on asenapine.

- check out Pfizer's brief release on the split
- see Organon's press release
- here's the AFX report on Pfizer's move

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.